Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Inter Pharma Public Company Limited (IP.BK)
Bangkok, TH
Based in Bangkok, Thailand, Inter Pharma Public Company Limited specializes in the manufacturing, importing, and distribution of a wide array of health and dietary supplements designed for both human and animal use. The company's operations are divided into two primary segments: Human Healthcare and Animal Healthcare. Its Human Healthcare division provides a diverse range of items including medical supplies, nutritional therapy products, cosmetics, supplemental foodstuffs, probiotic and prebiotic offerings, health-focused and general food products, medical devices, and pharmaceutical medicines. This segment also extends to wellness and anti-aging solutions, aesthetic treatments like anti-wrinkle creams, hyaluronic fillers, and EGF cosmeceuticals, as well as diagnostic tools. For the Animal Healthcare sector, Inter Pharma caters to pets and livestock with veterinary provisions, nutritional support, vaccines, supplementary feeds, probiotic and prebiotic formulations, specialized animal health foods, premium and standard animal feeds, nutraceuticals, medicated shampoos, animal cosmeceuticals, and general pet and livestock food products. The company was founded in 2006 and is headquartered in Bangkok.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.49% | +2.48% | +0.98% | +3.50% | -10.00% | +27.78% | -39.91% | -67.32% | +35.29% | +35.29% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+15.6% ★ Q1'26: +5.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+224.7% ★ Q1'26: +38.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+5.4% ★ Q1'26: +6.6% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+7.8% ★ Q1'26: +9.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+5.6% ★ Q1'26: +7.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.39× Q1'26: 1.11× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
371.33M
est: 378.00M (-1.8%)
|
442.10M
est: 438.50M (+0.8%)
|
908.63M
est: 866.50M (+4.9%)
|
1.52B
est: 1.56B (-2.2%)
|
1.78B
est: 1.81B (-1.5%)
|
1.90B
est: 2.26B (-16.2%)
|
2.19B
est: 1.61B (+36.5%)
|
| EBITDA |
63.61M
est: 54.67M (+16.4%)
|
82.64M
est: 63.42M (+30.3%)
|
172.38M
est: 125.32M (+37.5%)
|
235.78M
est: 225.19M (+4.7%)
|
167.66M
est: 241.49M (-30.6%)
|
185.20M
est: 302.15M (-38.7%)
|
288.15M
est: 214.56M (+34.3%)
|
| EBIT |
61.77M
est: 41.31M (+49.5%)
|
76.95M
est: 47.93M (+60.6%)
|
145.77M
est: 94.71M (+53.9%)
|
170.80M
est: 170.18M (+0.4%)
|
109.40M
est: 162.99M (-32.9%)
|
73.94M
est: 203.93M (-63.7%)
|
171.40M
est: 144.82M (+18.4%)
|
| Net Income |
43.47M
est: 90.32M (-51.9%)
|
52.54M
est: 93.96M (-44.1%)
|
105.22M
est: 117.35M (-10.3%)
|
118.88M
est: 141.56M (-16.0%)
|
50.79M
est: 27.42M (+85.2%)
|
37.28M
est: 167.63M (-77.8%)
|
122.38M
est: 208.61M (-41.3%)
|
| SGA |
156.73M
est: 126.94M (+23.5%)
|
187.22M
est: 147.25M (+27.1%)
|
267.36M
est: 290.98M (-8.1%)
|
457.88M
est: 522.86M (-12.4%)
|
567.58M
est: 561.24M (+1.1%)
|
649.10M
est: 702.21M (-7.6%)
|
649.11M
est: 498.66M (+30.2%)
|
| EPS |
0.15
est: 0.15 (+0.5%)
|
0.21
est: 0.16 (+35.3%)
|
0.36
est: 0.19 (+85.7%)
|
0.36
est: 0.23 (+53.9%)
|
0.14
est: 0.05 (+209.1%)
|
0.06
est: 0.28 (-77.8%)
|
0.20
est: 0.34 (-42.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Apimon Posri | Chief of Human Resources & Director | — | female |
| Chatkaew Krudkosol | Acting Chief of Financial & Accounting | — | female |
| Chompunuch Meevang | Company Secretary, Head of Investor Relations & Head of Compliance | — | female |
| Napaporn Dechakarat | Chief Operating Officer & Director | — | female |
| Supaporn Chanwongngam | Accounting Manager | — | female |
| Trinnawat Thanitnithiphan | Chief Executive Officer, Acting Chief of Marketing and Sales & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IP.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
